Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin plus tucatinib in HER2-expressing advanced solid tumors (Japan Phase 1b/2)
jRCT2031250697Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Feb 2026
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of disitamab vedotin and tucatinib in breast cancer and Nonhematologic neoplasms (2 cohorts), sponsored by Pfizer. Primary endpoints: Number of participants with dose limiting toxicities (DLTs) in dose escalation phase, Number of participants with adverse events (AEs) and 3 more. Started Feb 2026; status: active, not recruiting.
02
Drugs
disitamab vedotintucatinib
03
Conditions
breast cancerNonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031250697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250697.